Catalyst
Slingshot members are tracking this event:
Incyte (INCY) Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INCY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 30, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Jakafi, Graft-versus-host Disease, Ruxolitinib
